KEY POINTS
• JAK2R 564 Q is the first germline JAK2 mutation found to contribute to a familial MPN that involves a residue other than V 617 .
• The kinase activity of JAK2R 564 Q and JAK2V 617 F are the same, but only V 617 F is able to escape regulation by SOCS3 and p27.
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INTRODUCTION
The discovery that the acquired JAK2 mutation, JAK2V 617 F, contributes to the Philadelphia chromosome-negative myeloproliferative neoplasms (MPNs) significantly advanced our understanding of these diseases [1] [2] [3] . We now know that this mutation in the pseudokinase domain of JAK2 contributes to the origins of about half of all patients with acquired essential thrombocythemia (ET) and primary myleofibrosis (PMF) and nearly all patients with acquired polycythemia vera (PV) [4] [5] [6] . More recently, other mutations, deletions or insertions in JAK2 7-9 , MPL 10,11 , KIT 12 , TET2 13,14 and SH2B3, which encodes LNK 15 have all been shown to contribute to the development of MPNs.
The JAK2 protein is comprised of a FERM (4-point, Erzin, Radixin, Moesin) domain at the N-terminus, followed by a SRC homology 2 (SH2)-like domain, a JAK homology-2 (JH2) pseudokinase domain and a JH1 active tyrosine kinase domain ( Figure 1E ). Occurring in the pseudokinase domain, the crystal structure of which has recently been published 16 , the JAK2V 617 F mutation is commonly thought to interrupt autoinhibitory interactions that would normally facilitate inhibition of the JH1 kinase activity by the JH2 pseudokinase domain. This acquired somatic mutation occurs at the level of the hematopoietic stem cell, giving rise to lineage-specific cells that are hypersensitive to cytokine stimulation. Several mechanisms have been reported to be responsible for mediating these effects. JAK2V 617 F down-regulates p27/Kip1, a cell cycle inhibitor at the G1 to S transition. Direct phosphorylation of p27/Kip1 by JAK2V 617 F impairs its ability to inhibit the growth promoting cell cycle kinase Cdk, and marks it for proteasomal degradation 17 . Activation of STAT5 by JAK2V 617 F also leads to increased transcription of Skp2, a subunit of ubiquitin E3 ligase, which further promotes p27/Kip1 degradation 18, 19 . Moreover, the normal control on over-exuberant cell growth, mediated by the suppressor of cytokine signaling 3 (SOCS3), that acts to regulate JAK2 activity, is also abrogated by JAK2V 617 F in BaF/3 cells 20 . SOCS3 expression, induced several hours after the For personal use only. on April 30, 2017. by guest www.bloodjournal.org From onset of JAK/STAT signaling, inhibits JAK2 activity, either through direct binding to the JH1 catalytic loop, or through generation of an E3 ligase that ubiquitinates JAK2 and targets it for degradation. However, in BaF/3 cells, SOCS3 is unable to regulate JAK2V 617 F, and paradoxically enhances its activity 20 . This effect may be context-dependent though, since it has also been reported that SOCS3 can inhibit JAK2V 617 F signaling through proteasomal degradation in HEK cells 21 .
Although JAK2V 617 F in exon 14 is the most common mutation of JAK2 associated with MPNs, insertion/deletion events in JAK2 exon 12 are also known contributors 8, 9 . A screening of blood samples from suspected MPN patients revealed further point mutations in exons 12-15 7 ,
although functional studies to confirm their contribution to disease pathogenesis have yet not been performed for many of these mutant kinases. Thus far, nearly every previously identified JAK2 alteration, found in patients with MPNs, including JAK2V 617 F, are somatic, acquired mutations. The single exception is JAK2V 617 I, recently proposed as a germline mutation associated with hereditary thrombocytosis 22, 23 . Here we describe for the first time a JAK2 mutation associated with a familial MPN that involves a residue other than Val 617 . This novel mutation in exon 13 of JAK2 is a single nucleotide substitution, g1691a, which results in an arginine to glutamine change at position 564 (JAK2R 564 Q). This mutation, present in three out of four of the studied family members, is associated with hereditary thrombocytosis and increased JAK2 activation in platelets. We have further shown that in cell lines the mutation leads to JAK2 hypersensitivity and increased cell growth due to suppression of apoptosis.
Despite being localized in the same pseudokinase domain as V 617 , and generating similar levels of increased JAK2 activity, the effects of JAK2R 564 Q are distinct from those of JAK2V 617 F. Like the wild-type kinase, proliferation of JAK2R 564 Q-Ba/F3-MPL cells is regulated by the cell cycle inhibitor, p27/Kip1, whereas JAK2V 617 F is able to decrease p27/Kip1 levels and escape this regulation. Furthermore, SOCS3 negatively regulates JAK2R 564 Q, as for wild-type kinase, but is 
MATERIALS AND METHODS

Patients and Samples
Written informed consent was obtained from patients in accordance with the Declaration of Helsinki and with approval from the Stony Brook University ethics committee. XCIP experiments were performed on patient myeloid cells according to 24 and analyzed on 3% agarose gels.
Platelet lysate collection and all other methods are described in supplemental data.
RESULTS
Case presentation and generation of JAK2R 564 Q cell lines
A 6 year old male with a prolonged, elevated platelet count (800-1300 x10 3 /µL, monitored over three years), negative for secondary thrombocytosis such as iron deficiency and inflammatory diseases, was diagnosed with ET (C1, Table 1) . A blood smear further confirmed increased platelet number ( Figure 1A ). Evaluation of the patient for MPN revealed a normal BCR-ABL PCR test, a normal karyotype, 46XY, and assessments for JAK2V 617 F, MPLW 515 and S 505 mutations were negative. However, sequence analysis revealed a novel JAK2 G-to-A mutation at nucleotide 1691 in exon 13 ( Figure 1B ), resulting in an amino acid substitution of arginine to glutamine at position 564 (JAK2R 564 Q, Figure 1C ). In addition, the patient's sister (C2) and mother (C3) were also thrombocytotic (500-600 x10 3 /µL platelet counts) and both tested positive for the JAK2R 564 Q mutation ( Figure 1D , Table 1 ). The father (C4), however, had platelet counts in the normal range and was negative for JAK2R 564 Q.
XCIP analysis was performed on myeloid cells from the two JAK2R 564 Q-positive female patients (C2 and C3) in order to assess clonality in hematopoietic cells. A polyclonal pattern with 57% expression of one allele was seen in C2, indicating that the JAK2R 564 Q mutation may be sufficient to drive the thrombocytosis, without the acquisition of additional somatic mutations. C3
showed 90% expression of the predominant allele, suggesting myeloid clonality and the possibility that an additional somatic mutation may be contributing to the mild thrombocytosis of this patient. Given the limitations of the assay 25 , and without determining clonality in T-cell controls, it is difficult to accurately interpret this imbalanced pattern.
R 564 is very highly conserved across species ( Figure 1E ). It is located in the JH2 pseudokinase domain ( Figure 1F ), along with the well-characterized JAK2V 617 F mutation. In order to determine the functional consequences of JAK2R 564 Q and compare them to those of JAK2V 617 F, we antibodies can distinguish between human and murine JAK2, expression of human JAK2 mRNA was verified by real time PCR using human specific primers. Levels of human JAK2 cDNA, normalized by endogenous mouse Jak2 cDNA levels, were quantified and no significant difference was observed between the four cell lines ( Figure 2B ). Similar levels of both total JAK2 and MPL protein were determined in all four cell lines by western blot analysis ( Figure   2C ). Cell surface expression of MPL was also measured by flow cytometry ( Figure 2D ) and no significant difference in cell surface MPL expression was found between the cell lines ( Figure   2E ).
Expression of JAK2R 564 Q causes increased intracellular signaling
To begin to understand the contribution of JAK2R 564 Q to the pathogenesis of familial thrombocytosis, we determined the effects of the mutation on JAK2 activity and signaling. The kinase activity of JAK2, JAK2R 564 Q, JAK2V 617 F and the combined mutant kinase were assessed using an in vitro kinase assay ( Figure 3A ). All three mutant forms of JAK2 showed a similar, approximate 3 fold, increase in activity compared to WT. However, there were no significant differences in kinase activity between each of the JAK2 mutants. To confirm the ability of the mutant JAK2s to phosphorylate MPL, cell lysates were immunoprecipitated with an anti-MPL antibody, before probing with an anti-phospho-Tyrosine antibody ( Figure 3B ). In the absence of to WT in the absence of, and at 1ng/ml and 10ng/ml TPO ( Figure 3C ). However, we also observed increased phosphorylation of the negative regulatory site JAK2Tyr 570 , suggesting a general global increase in JAK2 tyrosine phosphorylation. Phosphorylated levels of the downstream signaling proteins STAT1, 3 and 5 were elevated in each of the mutant JAK2 cell lines, especially in the absence of TPO ( Figure 3C ). We also found higher levels of pSTAT1 and pSTAT3 in cells expressing JAK2V 617 F, compared to JAK2R 564 Q. Total STAT1 levels were also increased with JAK2R 564 Q expression, compared to WTJAK2 and this effect was even more prominent with JAK2V 617 F. An overall increase in downstream signaling in mutant JAK2 cells under starved conditions was further demonstrated ( Figure 3D ). Tyrosine-phosphorylation of proteins was also up-regulated in JAK2R 564 Q-expressing cells, compared to WTJAK2, and this was even more robust in the JAK2V 617 F-expressing mutants ( Figure 3D ). Furthermore, similar increased signaling was observed in JAK2R 564 Q-positive patients ( Figure 3E ). Platelets were isolated from 3 members of the family with the JAK2R 564 Q mutation and subject to western blot analysis. Phosphorylation of JAK2 was increased in the JAK2R 564 Q-positive family members (R564Q#1 and #2), compared to the father, who is negative for the mutation (WT). The growth characteristics of the JAK2-expressing cell lines in response to TPO-treatment were then determined using MTT assays. Cells expressing JAK2V 617 F, either with or without JAK2R 564 Q, were factor independent and proliferation was significantly increased from WTJAK2-expressing cells in the absence of, and at all concentrations of TPO ( Figure 4A ).
JAK2R 564 Q-expressing cells also showed significantly increased proliferation, compared to 1 1 WTJAK2 cells, although cell proliferation was much less striking than with JAK2V 617 F, and was still responsive to cytokine stimulation ( Figure 4A ). We hypothesized that the mild hyperproliferative phenotype of JAK2R 564 Q cells compared to WT controls, was possibly due to a decrease in apoptosis in the absence of, or at low concentrations of TPO.
To test this hypothesis, cells were grown in the absence of cytokine and viable cells were counted every 24hrs ( Figure 4B ). Viable cell number dropped significantly even after only 24hrs in WTJAK2-expressing cells, whereas a significant increase was seen in the number of cells expressing JAK2V 617 F, confirming their factor independence. However, the JAK2R 564 Qexpressing cells exhibited no significant change in cell number over the 72 hour period. These data indicate that while the JAK2R 564 Q mutation may not stimulate cell proliferation in the absence of cytokine, it inhibits apoptosis.
To confirm this finding, following cytokine starvation we determined the percentage of apoptotic cells every 24hrs by annexin V staining ( Figure 4C ). The vast majority of WT cells were apoptotic by 48hrs of starvation (approximately 70%), whereas the number of apoptotic cells in JAK2V 617 F-expressing cell lines was significantly less (approximately 35%). Supporting our previous results, apoptosis was attenuated in JAK2R 564 Q-positive cells (approximately 42% after 48hrs). Concurrent with these findings, higher levels of uncleaved PARP with prolonged starvation was also observed in cells expressing JAK2R 564 Q, compared to WTJAK2, by western blot ( Figure 4D ). However, levels of uncleaved PARP were even higher in the JAK2V 617 F and double mutants.
Next, we determined whether any of the cell lines were able to proliferate in the absence of cytokine using BrdU assays ( Figure 4E ). JAK2R 564 Q exhibited only a modest increase in the number of cycling cells compared to control and only after 48hrs. Cell lines with the JAK2V 617 F mutation, however, continued to actively proliferate for the entire 48hrs, with only a slight For personal use only. on April 30, 2017. by guest www.bloodjournal.org From decrease compared to cells grown with cytokine. Expression of cell cycle regulators was further examined ( Figure 4F ). Levels of p27/Kip1, the negative regulator of the G1 to S phase transition, increased in both WTJAK2 and JAK2R 564 Q-expressing cells with prolonged starvation. However, p27/Kip1 levels remained low in the JAK2V 617 F-expressing cells throughout the 36hr period, suggesting a mechanism by which proliferation might be enhanced in these cells, compared to those expressing JAK2R 564 Q. p21/CIP/WAF1 levels remained constant in WTJAK2 and JAK2R 564 Q-expressing cells throughout the 36hr period, although they were increased after 12hrs in the JAK2V 617 F-expressing cells. As p21 is also a cyclin-dependent kinase inhibitor, it may be involved in negative feedback to inhibit JAK2V 617 F cell proliferation.
However, if the effects of p21 are less potent than those of p27, this may explain the differences in proliferation. Therefore, we concluded that the differences in cell cycle behavior between JAK2V 617 F-and JAK2R 564 Q-expressing cells were accounted for by p27 and not p21. Taken together, this data strongly suggests that the JAK2R 564 Q mutation is able to inhibit apoptosis in the absence of cytokines, but does not stimulate proliferation.
To determine whether JAK2R 564 Q can also signal through EPOR, rather than MPL, we generated a Ba/F3 cell line that stably expresses the human EPOR (Ba/F3-EPOR), then further transfected a single Ba/F3-EPOR clone with WTJAK2, JAK2R 564 Q or JAK2V 617 F. Each of the cell lines showed similar levels of both total JAK2 and EPOR (supplemental Figure 1A) . As shown by others 1 , JAK2V 617 F-expression was still able to increase cell growth in Ba/F3-EPOR cells, compared to WTJAK2 (supplemental Figure 1B) . However, JAK2R 564 Q expression had no effect on cell growth, compared to WTJAK2 despite causing a modest increase in the phosphorylation of signaling proteins (supplemental Figure 1C) . Therefore, it appears that JAK2R 564 Q can only exert its proliferation-enhancing effects by signaling through MPL, and not EPOR.
For personal use only. on April 30, 2017. by guest www.bloodjournal.org From JAK2R 564 Q is negatively regulated by SOCS3 overexpression SOCS proteins negatively regulate JAK2 activity, either through direct inhibition, or by stimulating the ubiquitination and subsequent degradation of the kinase. To explore whether SOCS proteins might also account for the differences in cell proliferation between JAK2V 617 F and JAK2R 564 Q in BaF-MPL cells, we next determined the endogenous levels of SOCS1 and 3 in the JAK2-expressing cell lines by western blot analysis ( Figure 5A ). Although SOCS1 expression was largely unaltered between WT and the mutant JAK2-expressing cell lines, SOCS3 levels were increased in all cell lines expressing mutant JAK2, compared to WT JAK2, both with and without TPO stimulation. Therefore, we next investigated the effect of SOCS3 overexpression in these cells ( Figure 5B ). In JAK2R 564 Q-expressing cells, the increased concentration of SOCS3 was associated with a decrease in pJAK2. However, this negative feedback was not observed in the JAK2V 617 F-expressing cells, where pJAK2 levels remained unaltered. Furthermore, we observed more ubiquitinated JAK2 in starved JAK2R 564 Qexpressing cells compared to starved WTJAK2-expressing cells, as there are more cells still proliferating in the absence of cytokine, and therefore presumably more stimulation of the negative feedback mechanism to unbiquitinate JAK2 and target it for proteasomal degradation ( Figure 5C ). Conversely, although JAK2V 617 F-expressing cells also proliferate more robustly than WTJAK2-expressing cells, in the absence of cytokine, ubiquitination levels of JAK2 were much lower in the JAK2V 617 F-bearing cells compared with those expressing JAK2R 564 Q. This may be due to an escape of the negative regulation by JAK2V 617 F, so that it is not ubiquitinylated for degradation in response to proliferation. JAK2R 564 Q is more sensitive to ruxolitinib than JAK2V 617 F Finally, to determine if any or all of these cellular differences might affect clinical responses to therapeutic JAK inhibition, we used a commercially available JAK inhibitor, ruxolitinib (Jakafi), to 1 4 observe the effects of inhibiting JAK activity in mutant JAK2-expressing cells ( Figure 5D ). Viable cell number was measured after incubation in increasing concentrations of ruxolitinib under starved conditions. The number of viable cells was significantly decreased by concentrations of 100nM ruxolitinib (p<0.05) and above in the JAK2V 617 F-expressing cell line. However, a significant decrease in cell viability, compared to DMSO controls was seen in the presence of only 0.1nM ruxolitinib (p<0.01) in JAK2R 564 Q-expressing cells and viability continued to decrease as the concentration of the JAK inhibitor was raised. Furthermore, increased activation of JAK2 was confirmed in the platelets of JAK2R 564 Q-positive family members, compared to those without the mutation.
In order to elucidate the cellular effects of JAK2R 564 Q, we generated Ba/F3-MPL cell lines that expressed either WTJAK2, JAK2R 564 Q, JAK2V 617 F, or both JAK2R 564 Q and JAK2V 617 F mutations. Interestingly, our results showed that despite JAK2R 564 Q and the well-described JAK2V 617 F mutation residing within the same region, and causing similar levels of increased JAK2 activity, these two mutations have differing effects on cell cycle and proliferation. The JAK2 kinase activity, pMPL and pJAK2 levels were all significantly increased compared to WTJAK2 controls, and were comparable in all of the JAK2 mutants. It is intriguing that despite the similar localization of the two MPN-causing mutations of JAK2, and the fact that they result in the same levels of increased kinase activity in biochemical assays, their effects in a cellular setting are very different; our results indicate this to be due to differences in the regulation of the kinase. p27/Kip1 levels are reduced in JAK2V 617 F-expressing cells, but not in JAK2R 564 Q-expressing cells, indicating that with JAK2V 617 F expression the cells can escape cell cycle regulation. In addition, JAK2R 564 Q is controlled by a negative feedback mechanism involving SOCS3, whereas the JAK2V 617 F mutant is not. It is conceivable that the patient with the JAK2R 564 Q mutation developed ET, rather than PV, due to the remaining presence of regulatory mechanisms that can somewhat control the hyperactivity caused by the JAK2 mutation. Recent reports have also shown allelic burden to have an important role in disease phenotype determination 30, 31 . We predict that the index patient in this study is heterozygous for JAK2R 564 Q, since his father does not carry the mutation. Our preliminary results also suggest that JAK2R 564 Q has a much stronger effect on cell viability when signaling through MPL than through EPOR. The panoply of signaling proteins that EPOR recruits is undoubtedly different to those recruited by MPL and we speculate that the proteins involved in MPL signaling may be more likely to interact with JAK2R 564 Q. This preference to signal through MPL may also provide a possible explanation of why the patient developed ET, rather than PV, since MPL predominantly drives platelet production.
Our studies further showed that JAK2V 617 F-expresing cells were sensitive to similar concentrations of the JAK inhibitor, ruxolitinib to those recently described using SET-2/UKE-1 were identified in a large screening of blood samples from suspected MPN patients 7 , although confirmation of their contribution to MPN is now required. As this region encodes the pseudokinase domain, these mutations, similar to JAK2V 617 F, may interrupt the regulation of JAK2 activity. As well as JAK2R 564 Q, the mutation JAK2R 564 L was also discovered in this study, highlighting the importance of Arg 564 and suggesting that mutation of this residue has specific consequences. The recently published crystal structure of the JH2 domain 16 revealed that the V 617 F mutation causes the stabilization of α -helix C in the N lobe of JH2, enabling transphosphorylation of the JH1 kinase domain and therefore hyperactivation of JAK2. However, the mechanism by which the JAK2R 564 Q mutation causes JAK2 hypersensitivity remains unclear.
One possible explanation, based in the JH2 domain crystal structure 16 , is that JAK2R 564 may form a hydrogen bond with JAK2H 538 ( Figure 6A ). Both JAK2H 538 L and JAK2K 539 I have been described as activating mutations in the SH2-pseudokinase domain linker 35 , possibly due to H 538 and K 539 facilitating an inhibitory interaction with the SH2 domain. The R 564 -H 538 hydrogen bond may position H 538 for this inhibitory interaction and anchor the rest of the kinase domain relative to the SH2 domain (Figure 6Bi ). This hydrogen bond would be broken in the JAK2R 564 Q mutant, 1 9 preventing the inhibitory interaction between H 538 and the SH2 domain, leading to JAK2 activation ( Figure 6Bii ). Further studies are now required to determine whether this is indeed the mechanism responsible.
The precise genetic foundations of familial MPNs have proven difficult to define (reviewed in 36 ).
Recently, familial thrombocytosis has been associated with a germline MPL mutation 37 and a TET2 truncation mutation 38 , but evidence so far has shown that JAK2 mutations, particularly JAK2V 617 F, are acquired independently by individuals. Although two recent reports have associated a germline JAK2V 617 I mutation with familial thrombocytosis 22,23 , our study is the first to demonstrate the contribution of a novel germline mutation involving an alternative JAK2 residue to MPN development and outlines the potential mechanisms responsible for causing familial thrombocytosis. We hypothesize that the JAK2R 564 Q mutation prevents apoptosis in hematopoietic stem cells and megakaryocyte progenitors, giving rise to a moderate increase in platelets. Importantly, even though this mutation is localized to the same JH2 pseudokinase domain, its effects on cell survival and proliferation are significantly different to the JAK2V 617 F mutation. Our work provides an insight into the functionality of alternative, clinically relevant JAK2 mutations and may aid in the development or modification of therapeutic strategies.
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